Article in Addiction biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Esteban S UrenaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.ORCID 0000-0003-1283-024X
Cody C DiezelDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.ORCID 0000-0003-3144-7342
Mauricio SernaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.
Grace Hala'ufiaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.
Lisa MajutaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.
Kara R BarberDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.
Todd W VanderahDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.
Arthur C RiegelDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.ORCID 0000-0001-7758-4436
Funding
MARC/Biomedical Research and Training Program at the University of ArizonaT34GM008718 · NIGMS · UNIVERSITY OF ARIZONA · PI MIRANDA, KATRINA M. · 1999 to 2021
$8.6M
The Center of Excellence in Addiction Studies (CEAS)P30DA051355 · NIDA · UNIVERSITY OF ARIZONA · PI PORRECA, FRANK, VANDERAH, TODD W · 2021 to 2025
$6.7M
THE ROLE OF RYANODINE RECEPTORS IN DRUG SEEKINGR01DA046476 · NIDA · UNIVERSITY OF ARIZONA · PI RIEGEL, ARTHUR C · 2018 to 2022
$1.9M
Center of Excellence in Addiction Studies DA051355Comprehensive Pain and Addiction-CenterKempner FoundationLouis Stokes Alliance for Minority ParticipationNational Science Foundation HRD-1101728NIDA NIH HHS P30 DA051355NIDA NIH HHS R01 DA046476NIDA NIH HHS R01DA046476NIGMS NIH HHS T34 GM008718Undergraduate Biology Research Program at the University of ArizonaWestern Alliance to Expand Student Opportunities
6 · The paper itself
Abstract
The increasing rates of drug misuse highlight the urgency of identifying improved therapeutics for treatment. Most drug-seeking behaviours that can be modelled in rodents utilize the repeated intravenous self-administration (SA) of drugs. Recent studies examining the mesolimbic pathway suggest that K
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.